Last reviewed · How we verify

Nicotine Gum

Fred Hutchinson Cancer Center · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Nicotine Gum is a Small molecule drug developed by Fred Hutchinson Cancer Center. It is currently FDA-approved. Also known as: Nicorette, Nicotine Polacrilex gum, Nicorette® Gum, NRT.

Nicotine gum is used to treat conditions such as smoking, tobacco use, tobacco dependence, tobacco use cessation, and nicotine addiction. The exact mechanism of nicotine gum is unknown, but it is known to contain nicotine, a substance found in the plant Cyamopsis tetragonoloba.

At a glance

Generic nameNicotine Gum
Also known asNicorette, Nicotine Polacrilex gum, Nicorette® Gum, NRT, Nicorrete gum
SponsorFred Hutchinson Cancer Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nicotine Gum

What is Nicotine Gum?

Nicotine Gum is a Small molecule drug developed by Fred Hutchinson Cancer Center.

Who makes Nicotine Gum?

Nicotine Gum is developed and marketed by Fred Hutchinson Cancer Center (see full Fred Hutchinson Cancer Center pipeline at /company/fred-hutchinson-cancer-center).

Is Nicotine Gum also known as anything else?

Nicotine Gum is also known as Nicorette, Nicotine Polacrilex gum, Nicorette® Gum, NRT, Nicorrete gum.

What development phase is Nicotine Gum in?

Nicotine Gum is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing